Browse News
Filter News
Found 2,192 articles
-
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
1/26/2023
CytomX Therapeutics, Inc. today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas.
-
Myosana Therapeutics Raises $5 Million in Seed Funding
1/25/2023
Myosana Therapeutics, Inc. today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D.
-
Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease.
-
DM Clinical Research Opens New Research Site in Boston Area
1/19/2023
DM Clinical Research, a national network of clinical trial sites, has opened its first research location in the Boston metropolitan area and Massachusetts.
-
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
1/19/2023
Sesen Bio, Inc. announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc., a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.
-
Moderna Racks Up Phase III RSV Success
1/18/2023
Moderna announced positive topline results from a Phase III trial with older adults and a vaccine candidate aimed at preventing respiratory syncytial virus. -
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
1/17/2023
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults.
-
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
1/17/2023
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 19, 2023 at 2:30 p.m. ET.
-
The drugmaker's presentation highlights its strong revenue growth, dominant vaccine business and expanding oncology portfolio.
-
JPM Day 1: Highlights
1/9/2023
Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week. -
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
1/9/2023
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates on its industry-leading mRNA pipeline. Moderna continues to scale, now with 48 programs in development, including 36 programs in clinical trials encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities.
-
Moderna and CytomX ink a cancer partnership.
-
Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners
1/6/2023
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the opening of Bioworks7, the latest expansion of its biological engineering foundry.
-
Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.
-
BioSpace’s exclusive Hotbed Maps highlights nine different regions to watch across the U.S. The maps, made in vibrant color for BioSpace showcases a one-of-a-kind glance at some of 2023’s headline-making companies.
-
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
1/5/2023
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors.
-
Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment
1/5/2023
Ophirex, Inc., a public benefit biotechnology company, announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF.
-
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
1/5/2023
Moderna, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform.
-
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
1/5/2023
CytomX Therapeutics, Inc. and Moderna, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody® therapeutic platform.
-
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
1/5/2023
CytomX Therapeutics, Inc. announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study.